Impact Factor
3.95
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.41
1,484 total citations
h5-index
59
h5 depth signal
Cited share
61.4%
172 of 280
Total citations
1,484
Citation footprint
Metric signal
5.96
External metric anchor
Self-citation
2.4%
35 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
498
United Kingdom
177
Italy
97
Canada
95
Australia
81
Citing Fields of Research
Urology
500
Prostate Cancer
443
Oncology
202
Kidney Diseases
162
Human Reproduction
91
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,720
Articles tracked across the journal lifetime
Indexed publication set
280
172 cited publications
Last 12 months
98
8.2 publications/month
Open access share
3.1%
3 OA publications in the last year
Leading citing country
United States
498 citing publications
Leading citing field
Urology
500 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v6n4, Apr. 2009-
v6n4, Apr. 2009-
Research Focus & Classification
Indexed Subjects
Urology
Prostate Cancer
Broad Categories
Urology
Prostate Cancer
Kidney Diseases
Human Reproduction
MeSH Descriptors
Female Urogenital Diseases
Male Urogenital Diseases
Urologic Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1038/s41585-026-01194-z
Open DOI
Rare prostate cancer histologies: detection, characteristics and treatment
02
DOI 10.1038/s41585-026-01193-0
Open DOI
Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies
Radical cystectomy is the current first-line treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer; however, this surgical procedure is associated with considerable morbidity and mortality. Bladder-preserving tr...
03
04
DOI 10.1038/s41585-026-01203-1
Open DOI
Return-to-play with a solitary kidney after renal tumour
05
DOI 10.1038/s41585-026-01192-1
Open DOI
Moving towards standardized outcomes in penile cancer and inguinal lymph node dissections
06
DOI 10.1038/s41585-026-01190-3
Open DOI
Update on testosterone deficiency and therapeutic options for testosterone replacement therapy
Testosterone deficiency, or male hypogonadism, is a clinical syndrome characterized by the presence of clinical features with persistently low serum testosterone levels. Testosterone deficiency is an important health concern owing to its...
07
08
DOI 10.1038/s41585-026-01188-x
Open DOI
Preclinical animal models of lower urinary tract dysfunction associated with metabolic syndrome
Lower urinary tract dysfunction (LUTD) substantially affects quality of life and is increasingly associated with metabolic syndrome (MetS). An intricate relationship exists between MetS components, such as obesity, diabetes, dyslipidaemi...
09
DOI 10.1038/s41585-026-01197-w
Open DOI
ctDNA in muscle-invasive bladder cancer — clinically actionable, not yet standardized
10
DOI 10.1038/s41585-026-01196-x
Open DOI
Evolution or revolution — the GALEAS Bladder molecular urine test for triaging patients with haematuria
Bibliographical & Catalog Notes
Description based on: Vol. 6, no. 4 (Apr. 2009); title from cover.
Latest issue consulted: Vol. 6, no. 4 (Apr. 2009).
Also issued online.